Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 11/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 11/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 10/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 10/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 10/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 9/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 8/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
| ▸ | GABRD | O14764 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | GABRE | P78334 | 1/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.44 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18172756 | 0.86 | GABRG2 (0.43) | GABRG2GABRB3GABRA1GABRA2GABRA5 | |
| SCHEMBL23361737 | 0.86 | GABRG2 (0.43) | GABRG2GABRB3GABRA1GABRA2GABRA5 | |
| SCHEMBL31037762 | 0.82 | P4HTM (0.63) | GABRG2GABRB3GABRA1GABRA2GABRA5 | |
| SCHEMBL8324962 | 0.81 | MAPK1 (0.61) | P4HTMMAPK1KDM4EMEN1ALDH1A1 | |
| SCHEMBL19556246 | 0.80 | NR1H2 (0.42) | GABRG2GABRB3GABRA1GABRA2GABRA5 | |
| SCHEMBL30554608 | 0.80 | KDM4E (0.40) | GABRG2GABRB3GABRA1GABRA2GABRA5 | |
| SCHEMBL30112027 | 0.80 | NR1H2 (0.42) | GABRG2GABRB3GABRA1GABRA2GABRA5 | |
| SCHEMBL19555927 | 0.80 | KDM4E (0.40) | GABRG2GABRB3GABRA1GABRA2GABRA5 | |
| SCHEMBL20719769 | 0.80 | KDM4E (0.40) | GABRG2GABRB3GABRA1GABRA2GABRA5 | |
| SCHEMBL16675788 | 0.80 | GABRA1 (0.48) | GABRG2GABRB3GABRA1GABRA2GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | GABRG2 2500/4885GABRB3 626/4885GABRA1 2275/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | GABRG2 2500/4885GABRB3 626/4885GABRA1 2275/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | GABRG2 2500/4885GABRB3 626/4885GABRA1 2275/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | GABRG2 2500/4885GABRB3 626/4885GABRA1 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.